Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Feb;69(2):235–241. doi: 10.1038/bjc.1994.45

Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin.

G Los 1, M J van Vugt 1, H M Pinedo 1
PMCID: PMC1968708  PMID: 8297720

Abstract

The combination of heat and chemotherapy was studied in an intraperitoneal tumour model. Rats bearing peritoneal CC531 tumours (2-6 mm) were treated i.p. with cDDP or CBDCA [maximal tolerated dose (MTD)] in combination with regional hyperthermia (41.5 degrees C, 1 h) of the peritoneal cavity. The addition of hyperthermia to the i.p. treatment led to a decrease in the MTD of cDDP by 33.3% at 41.5 degrees C. This was due to increased nephrotoxicity. The MTD of CBDCA did not change as a result of hyperthermia treatment. The chemo-hyperthermia treatment resulted in more cDDP or CBDCA DNA adducts in peritoneal tumours after the combined treatment than after chemotherapy alone. The increased tumour platinum concentrations, rising from 1.3 micrograms Pt g-1 tumour at 37 degrees C to 5.4 micrograms Pt g-1 tumour at 41.5 degrees C for cDDP and from 0.2 microgram Pt g-1 tumor to 0.7 microgram Pt g-1 tumour at 41.5 degrees C for CBDCA, contributed considerably to the enhanced numbers of cDDP or CBDCA DNA adducts. As a result of the latter, i.p. chemotherapy combined with regional hyperthermia led to an increase in tumour growth delay (TGD) after increasing the temperature to 41.5 degrees C for cDDP and CBDCA (by 40 days for cDDP, 22 days for CBDCA). These data were in agreement with the in vitro findings, i.e. that higher temperatures led to increased cytotoxicity.

Full text

PDF
235

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alberts D. S., Young L., Mason N., Salmon S. E. In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin Oncol. 1985 Sep;12(3 Suppl 4):38–42. [PubMed] [Google Scholar]
  2. Arancia G., Crateri Trovalusci P., Mariutti G., Mondovì B. Ultrastructural changes induced by hyperthermia in Chinese hamster V79 fibroblasts. Int J Hyperthermia. 1989 May-Jun;5(3):341–350. doi: 10.3109/02656738909140460. [DOI] [PubMed] [Google Scholar]
  3. Barlogie B., Corry P. M., Drewinko B. In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C. Cancer Res. 1980 Apr;40(4):1165–1168. [PubMed] [Google Scholar]
  4. Dahl O. Interaction of hyperthermia and chemotherapy. Recent Results Cancer Res. 1988;107:157–169. doi: 10.1007/978-3-642-83260-4_23. [DOI] [PubMed] [Google Scholar]
  5. Dunnick N. R., Jones R. B., Doppman J. L., Speyer J., Myers C. E. Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics. AJR Am J Roentgenol. 1979 Aug;133(2):221–223. doi: 10.2214/ajr.133.2.221. [DOI] [PubMed] [Google Scholar]
  6. Elferink F., van der Vijgh W. J., Klein I., ten Bokkel Huinink W. W., Dubbelman R., McVie J. G. Pharmacokinetics of carboplatin after intraperitoneal administration. Cancer Chemother Pharmacol. 1988;21(1):57–60. doi: 10.1007/BF00262740. [DOI] [PubMed] [Google Scholar]
  7. Hahn G. M., Braun J., Har-Kedar I. Thermochemotherapy: synergism between hyperthermia (42-43 degrees) and adriamycin (of bleomycin) in mammalian cell inactivation. Proc Natl Acad Sci U S A. 1975 Mar;72(3):937–940. doi: 10.1073/pnas.72.3.937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hahn G. M. Potential for therapy of drugs and hyperthermia. Cancer Res. 1979 Jun;39(6 Pt 2):2264–2268. [PubMed] [Google Scholar]
  9. Hahn G. M., Shiu E. C. Effect of pH and elevated temperatures on the cytotoxicity of some chemotherapeutic agents on Chinese hamster cells in vitro. Cancer Res. 1983 Dec;43(12 Pt 1):5789–5791. [PubMed] [Google Scholar]
  10. Herman T. S., Teicher B. A., Chan V., Collins L. S., Kaufmann M. E., Loh C. Effect of hyperthermia on the action of cis-diamminedichloroplatinum(II), rhodamine 123(2) [tetrachloroplatinum(II)], rhodamine 123, and potassium tetrachloroplatinate in vitro and in vivo. Cancer Res. 1988 May 1;48(9):2335–2341. [PubMed] [Google Scholar]
  11. Howell S. B., Pfeifle C. L., Wung W. E., Olshen R. A., Lucas W. E., Yon J. L., Green M. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med. 1982 Dec;97(6):845–851. doi: 10.7326/0003-4819-97-6-845. [DOI] [PubMed] [Google Scholar]
  12. Kerr D. J., Kaye S. B. Aspects of cytotoxic drug penetration, with particular reference to anthracyclines. Cancer Chemother Pharmacol. 1987;19(1):1–5. doi: 10.1007/BF00296245. [DOI] [PubMed] [Google Scholar]
  13. Knox R. J., Friedlos F., Lydall D. A., Roberts J. J. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res. 1986 Apr;46(4 Pt 2):1972–1979. [PubMed] [Google Scholar]
  14. Konings A. W. Membranes as targets for hyperthermic cell killing. Recent Results Cancer Res. 1988;109:9–21. doi: 10.1007/978-3-642-83263-5_2. [DOI] [PubMed] [Google Scholar]
  15. Levin L., Hryniuk W. M. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol. 1987 May;5(5):756–767. doi: 10.1200/JCO.1987.5.5.756. [DOI] [PubMed] [Google Scholar]
  16. Los G., McVie J. G. Experimental and clinical status of intraperitoneal chemotherapy. Eur J Cancer. 1990;26(6):755–762. doi: 10.1016/0277-5379(90)90137-i. [DOI] [PubMed] [Google Scholar]
  17. Los G., Mutsaers P. H., Lenglet W. J., Baldew G. S., McVie J. G. Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol. 1990;25(6):389–394. doi: 10.1007/BF00686048. [DOI] [PubMed] [Google Scholar]
  18. Los G., Mutsaers P. H., van der Vijgh W. J., Baldew G. S., de Graaf P. W., McVie J. G. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res. 1989 Jun 15;49(12):3380–3384. [PubMed] [Google Scholar]
  19. Los G., Smals O. A., van Vugt M. J., van der Vlist M., den Engelse L., McVie J. G., Pinedo H. M. A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity. Cancer Res. 1992 Mar 1;52(5):1252–1258. [PubMed] [Google Scholar]
  20. Los G., Sminia P., Wondergem J., Mutsaers P. H., Havemen J., ten Bokkel Huinink D., Smals O., Gonzalez-Gonzalez D., McVie J. G. Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur J Cancer. 1991;27(4):472–477. doi: 10.1016/0277-5379(91)90389-u. [DOI] [PubMed] [Google Scholar]
  21. Los G., Tuyt L., van Vugt M., Schornagel J., Pinedo H. M. Combination treatment of cis- and carboplatin in cancers restricted to the peritoneal cavity in the rat. Cancer Chemother Pharmacol. 1993;32(6):425–433. doi: 10.1007/BF00685885. [DOI] [PubMed] [Google Scholar]
  22. Los G., Verdegaal E. M., Mutsaers P. H., McVie J. G. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol. 1991;28(3):159–165. doi: 10.1007/BF00685503. [DOI] [PubMed] [Google Scholar]
  23. Markman M. Intraperitoneal chemotherapy. Semin Oncol. 1991 Jun;18(3):248–254. [PubMed] [Google Scholar]
  24. Marquet R. L., Westbroek D. L., Jeekel J. Interferon treatment of a transplantable rat colon adenocarcinoma: importance of tumor site. Int J Cancer. 1984 May 15;33(5):689–692. doi: 10.1002/ijc.2910330521. [DOI] [PubMed] [Google Scholar]
  25. Ozols R. F., Locker G. Y., Doroshow J. H., Grotzinger K. R., Myers C. E., Young R. C. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res. 1979 Aug;39(8):3209–3214. [PubMed] [Google Scholar]
  26. Riviere J. E., Page R. L., Dewhirst M. W., Tyczkowska K., Thrall D. E. Effect of hyperthermia on cisplatin pharmacokinetics in normal dogs. Int J Hyperthermia. 1986 Oct-Dec;2(4):351–358. doi: 10.3109/02656738609004965. [DOI] [PubMed] [Google Scholar]
  27. Spratt J. S., Adcock R. A., Sherrill W., Travathen S. Hyperthermic peritoneal perfusion system in canines. Cancer Res. 1980 Feb;40(2):253–255. [PubMed] [Google Scholar]
  28. Terheggen P. M., Floot B. G., Lempers E. L., van Tellingen O., Begg A. C., den Engelse L. Antibodies against cisplatin-modified DNA and cisplatin-modified (di)nucleotides. Cancer Chemother Pharmacol. 1991;28(3):185–191. doi: 10.1007/BF00685507. [DOI] [PubMed] [Google Scholar]
  29. Terheggen P. M., Floot B. G., Scherer E., Begg A. C., Fichtinger-Schepman A. M., den Engelse L. Immunocytochemical detection of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in rodent tissue sections. Cancer Res. 1987 Dec 15;47(24 Pt 1):6719–6725. [PubMed] [Google Scholar]
  30. West G. W., Weichselbaum R., Little J. B. Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy. Cancer Res. 1980 Oct;40(10):3665–3668. [PubMed] [Google Scholar]
  31. Wondergem J., Bulger R. E., Strebel F. R., Newman R. A., Travis E. L., Stephens L. C., Bull J. M. Effect of cis-diamminedichloroplatinum(II) combined with whole body hyperthermia on renal injury. Cancer Res. 1988 Jan 15;48(2):440–446. [PubMed] [Google Scholar]
  32. Zakris E. L., Dewhirst M. W., Riviere J. E., Hoopes P. J., Page R. L., Oleson J. R. Pharmacokinetics and toxicity of intraperitoneal cisplatin combined with regional hyperthermia. J Clin Oncol. 1987 Oct;5(10):1613–1620. doi: 10.1200/JCO.1987.5.10.1613. [DOI] [PubMed] [Google Scholar]
  33. ten Bokkel Huinink W. W., Dubbelman R., Aartsen E., Franklin H., McVie J. G. Experimental and clinical results with intraperitoneal cisplatin. Semin Oncol. 1985 Sep;12(3 Suppl 4):43–46. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES